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prevalence of preHTN and HTN was 56.8% and 25.0% in males, and 43.1%
and 36.1% in females, respectively. Subjects with preHTN and those with
HTN showed higher prevalence of diabetes, dyslipidemia, obesity and abdom-
inal obesity than the normotensive (NT) group. The risk of developing CHD
within 10 years was above 15% for 3.9%, 31.1% and 65.0% among NT,
preHTN and HTN subjects, respectively. In multivariate analysis, preHTN
was associated with age, male gender, obesity, abdominal obesity and
smoking. In total, preHTN is very common in Tunisians. It is associated with
a higher prevalence of cardio-metabolic risk factors and confers a higher risk
for subsequent CHD. These findings support the recommendations of lifestyle
modification for preHTN patients.
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Objective: It has been shown that blood levels of Lipoprotein-associated
phospholipase A2 (Lp-PLA2) predict future cardiovascular events regarding
the presence of any other traditional cardiovascular (CV) risk factors except
LDL-Cholesterol (LDL-C). The aim of our study was to assess possible links
between Lp-PLA2 and LDL and HDL subclasses.
Methods: Overweighed and obese patients with no history of cardiovas-
cular disease were recruited at our outpatient clinic and all underwent routine
clinical and biological evaluation, as well as LDL and HDL subclasses deter-
mination. None was under any lipid lowering treatment. Lp-PLA2 was mea-
sured in serum with a Plac test turbidimetric immunoassay.
Results: 49 patients were included. Mean body mass index was
31.84kg/m² (sd: 3.45). The Lp-PLA2 ranged from 41 to 407 ng/mL; mean
value was 201 ng/mL (sd: 73). Mean values for total cholesterol, LDL-C,
HDL-C and apoB were respectively 2.31 g/L (sd: 0.38), 1.39 g/L (sd: 0.32),
0.47 g/L (sd: 0.13), and 1.27 g/L (sd: 0.25). 18 patients (37%) had dia-
betes. Mean HDL2b percentage was 11.47% (sd: 7.48). Mean HDL3b per-
centage was 27.22 % (sd: 9.22). In univariate analysis, we found a strong
linear correlation between Lp-PLA2, and LDL-C (r=0.42, p<0.028) as well
as apoB (r=0.31, p=0.02) and total cholesterol (r=0.44, p=0.001). There
was no correlation between percentages of LDL subclasses (LDL 1,2,3 and
4) or LDL size peak and Lp-PLA2 levels. We found no correlation with
total HDL-C but a positive correlation with HDL2b percentage (r=0.29,
p=0.04) and a negative association with HDL3b percentage (r=–0.3,
p=0.03). Neither ApoA1 (r=0.061) nor ApoA2 (r=0.059) were correlated
with Lp-PLA2 dosages. 
Conclusion: In our population, LpPLA2 was related with total LDL-C
levels without any significant relation with the LDL subclasses distribu-
tion. By contrast, LpPLA2 was not correlated with HDL-C level but with
HDL subclasses. Interestingly, LpPLA2 was negatively correlated with
HDL3b and positively with large HDL particles (HDL2b). This supports
differential properties of HDL subclasses in atherosclerosis and suggests a
potential interaction between HDL and LpPLA2.
